Yahoo Finance Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Daix (France), Long Island City (New York, United States), January 30, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.
Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of December 31, 2022:
Cash: € 282,479.85
Number of shares: 113,003
Number of executions on buy side on semester: 541
Number of executions on sell side on semester: 491
Traded volume on buy side on semester: 116,853 shares for € 574,407.24
Traded volume on sell side on semester: 103,989 shares for € 540,127.34
At the last half-year report as of June 30, 2022, the following resources were available in the liquidity account:
Cash: € 316,759.75
Number of shares: 100,139
Number of executions on buy side on semester: 993
Number of executions on sell side on semester: 636
Traded volume on buy side on semester: 152,845 shares for € 1,470,441.72
Traded volume on sell side on semester: 98,168 shares for € 1,025,659.18
When the contract was initially implemented, the following resources were included in the liquidity account:
Cash: € 163,510.42
Number of shares: 34,063
| Buy Side |
| Sell Side | |||||
| Number of | Number of | Traded volume in EUR |
| Number of | Number of | Traded volume in EUR | |
Total | 1534 | 269698 | 2 044 848,96 |
| 1127 | 202157 | 1 565 786,52 | |
03/01/2022 | 8 | 1000 | 11 800,00 |
| 12 | 2471 | 29 553,16 | |
04/01/2022 | 33 | 4501 | 53 336,85 |
| 11 | 2000 | 24 160,00 | |
05/01/2022 | 20 | 1950 | 22 542,00 |
| 2 | 500 | 5 850,00 | |
06/01/2022 | 3 | 49 | 563,50 |
| - | - | - | |
07/01/2022 | 38 | 3187 | 36 013,10 |
| - | - | - | |
10/01/2022 | 30 | 3999 | 43 709,07 |
| - | - | - | |
11/01/2022 | 7 | 1000 | 10 680,00 |
| 13 | 2060 | 22 309,80 | |
12/01/2022 | 12 | 2000 | 22 160,00 |
| 9 | 3440 | 38 872,00 | |
13/01/2022 | 9 | 500 | 5 480,00 |
| - | - | - | |
14/01/2022 | 5 | 1500 | 16 380,00 |
| 21 | 1614 | 17 931,54 | |
17/01/2022 | 2 | 1000 | 10 980,00 |
| 7 | 639 | 7 099,29 | |
19/01/2022 | 3 | 222 | 2 442,00 |
| - | - | - | |
20/01/2022 | 1 | 1 | 11,20 |
| 19 | 3008 | 33 689,60 | |
21/01/2022 | 8 | 1234 | 13 771,44 |
| 6 | 203 | 2 285,78 | |
24/01/2022 | 30 | 5265 | 57 072,60 |
| - | - | - | |
25/01/2022 | 1 | 1 | 10,54 |
| - | - | - | |
26/01/2022 | - | - | - |
| 8 | 1500 | 16 125,00 | |
27/01/2022 | 3 | 1000 | 10 680,00 |
| 5 | 500 | 5 400,00 | |
28/01/2022 | 8 | 1319 | 14 179,25 |
| 17 | 2537 | 27 627,93 | |
31/01/2022 | 15 | 1932 | 20 614,44 |
| 9 | 2000 | 21 560,00 | |
01/02/2022 | - | - | - |
| 31 | 5500 | 61 105,00 | |
02/02/2022 | - | - | - |
| 8 | 1000 | 11 800,00 | |
03/02/2022 | 10 | 2000 | 22 720,00 |
| 11 | 827 | 9 436,07 | |
04/02/2022 | 4 | 501 | 5 691,36 |
| 24 | 1565 | 17 966,20 | |
07/02/2022 | 3 | 500 | 5 750,00 |
| 9 | 2000 | 23 340,00 | |
08/02/2022 | 3 | 501 | 5 811,60 |
| 17 | 3000 | 35 580,00 | |
09/02/2022 | 7 | 1501 | 17 666,77 |
| 16 | 1500 | 17 880,00 | |
10/02/2022 | - | - | - |
| 1 | 50 | 598,00 | |
11/02/2022 | 8 | 542 | 6 449,80 |
| 4 | 950 | 11 381,00 | |
14/02/2022 | 27 | 4852 | 56 380,24 |
| - | - | - | |
15/02/2022 | 4 | 500 | 5 530,00 |
| - | - | - | |
16/02/2022 | 4 | 500 | 5 550,00 |
| 3 | 501 | 5 641,26 | |
17/02/2022 | 25 | 2501 | 27 511,00 |
| 1 | 422 | 4 709,52 | |
18/02/2022 | 4 | 1000 | 10 860,00 |
| 12 | 2185 | 23 947,60 | |
21/02/2022 | 31 | 3546 | 38 119,50 |
| - | - | - | |
22/02/2022 | 23 | 3648 | 37 428,48 |
| 5 | 755 | 7 776,50 | |
23/02/2022 | - | - | - |
| 40 | 4245 | 44 827,20 | |
24/02/2022 | 31 | 5306 | 53 272,24 |
| 2 | 155 | 1 612,00 | |
| Buy Side |
| Sell Side | |||||
| Number of | Number of | Traded volume in EUR |
| Number of | Number of | Traded volume in EUR | |
Total | 1534 | 269698 | 2 044 848,96 |
| 1127 | 202157 | 1 565 786,52 | |
25/02/2022 | - | - | - |
| 36 | 4345 | 45 622,50 | |
28/02/2022 | 4 | 500 | 5 250,00 |
| 7 | 3500 | 38 360,00 | |
01/03/2022 | 6 | 1749 | 19 169,04 |
| 10 | 2109 | 23 768,43 | |
02/03/2022 | 16 | 2548 | 27 696,76 |
| - | - | - | |
03/03/2022 | 11 | 1842 | 19 506,78 |
| - | - | - | |
04/03/2022 | 16 | 2058 | 21 403,20 |
| - | - | - | |
07/03/2022 | 27 | 5430 | 52 671,00 |
| 10 | 2500 | 24 750,00 | |
08/03/2022 | 5 | 1501 | 14 964,97 |
| 8 | 2501 | 25 760,30 | |
09/03/2022 | 6 | 1000 | 9 950,00 |
| 2 | 548 | 5 540,28 | |
10/03/2022 | - | - | - |
| 3 | 500 | 5 050,00 | |
11/03/2022 | 6 | 1000 | 9 950,00 |
| - | - | - | |
14/03/2022 | 4 | 1500 | 15 060,00 |
| 6 | 500 | 5 050,00 | |
15/03/2022 | 17 | 2500 | 24 575,00 |
| 1 | 23 | 227,70 | |
16/03/2022 | 6 | 500 | 5 000,00 |
| 11 | 1977 | 19 849,08 | |
17/03/2022 | 8 | 1000 | 10 100,00 |
| 7 | 1452 | 14 955,60 | |
18/03/2022 | 4 | 500 | 5 050,00 |
| 1 | 94 | 958,80 | |
21/03/2022 | 4 | 1000 | 10 000,00 |
| 2 | 407 | 4 192,10 | |
22/03/2022 | 5 | 251 | 2 530,08 |
| 14 | 1999 | 20 409,79 | |
23/03/2022 | 3 | 500 | 5 150,00 |
| 2 | 500 | 5 200,00 | |
24/03/2022 | 6 | 500 | 5 100,00 |
| - | - | - | |
25/03/2022 | 12 | 926 | 9 454,46 |
| 2 | 260 | 2 678,00 | |
28/03/2022 | 4 | 500 | 5 095,00 |
| 4 | 548 | 5 638,92 | |
29/03/2022 | 2 | 501 | 5 110,20 |
| 14 | 2457 | 25 307,10 | |
30/03/2022 | 3 | 311 | 3 234,40 |
| 3 | 495 | 5 148,00 | |
31/03/2022 | 11 | 542 | 5 631,38 |
| - | - | - | |
01/04/2022 | 8 | 1234 | 12 685,52 |
| - | - | - | |
04/04/2022 | 5 | 598 | 6 099,60 |
| 6 | 1000 | 10 320,00 | |
05/04/2022 | 1 | 228 | 2 325,60 |
| 2 | 500 | 5 150,00 | |
06/04/2022 | 1 | 137 | 1 397,40 |
| 1 | 6 | 61,80 | |
07/04/2022 | 3 | 500 | 5 100,00 |
| 3 | 170 | 1 751,00 | |
08/04/2022 | 5 | 473 | 4 777,30 |
| 2 | 2 | 20,40 | |
11/04/2022 | 1 | 485 | 4 898,50 |
| 8 | 998 | 10 179,60 | |
12/04/2022 | 10 | 1000 | 10 150,00 |
| 3 | 867 | 8 886,75 | |
13/04/2022 | 17 | 1599 | 15 910,05 |
| - | - | - | |
14/04/2022 | 17 | 1500 | 14 655,00 |
| 1 | 100 | 990,00 | |
19/04/2022 | - | - | - |
| 2 | 500 | 4 900,00 | |
20/04/2022 | 1 | 1 | 9,70 |
| 20 | 1500 | 14 850,00 | |
21/04/2022 | 2 | 6 | 59,28 |
| 6 | 500 | 5 000,00 | |
| Buy Side |
| Sell Side | |||||
| Number of | Number of | Traded volume in EUR |
| Number of | Number of | Traded volume in EUR | |
Total | 1534 | 269698 | 2 044 848,96 |
| 1127 | 202157 | 1 565 786,52 | |
22/04/2022 | 5 | 495 | 4 900,50 |
| - | - | - | |
25/04/2022 | 20 | 1782 | 17 231,94 |
| 1 | 7 | 69,30 | |
26/04/2022 | 11 | 2401 | 22 425,34 |
| - | - | - | |
27/04/2022 | 6 | 2005 | 17 984,85 |
| - | - | - | |
28/04/2022 | 1 | 20 | 180,00 |
| 8 | 1250 | 11 400,00 | |
29/04/2022 | - | - | - |
| 7 | 2000 | 18 500,00 | |
02/05/2022 | 4 | 500 | 4 600,00 |
| 11 | 550 | 5 120,50 | |
03/05/2022 | 3 | 150 | 1 392,00 |
| - | - | - | |
05/05/2022 | 2 | 102 | 938,40 |
| 1 | 450 | 4 230,00 | |
06/05/2022 | 6 | 898 | 8 315,48 |
| - | - | - | |
09/05/2022 | 14 | 1980 | 17 919,00 |
| - | - | - | |
11/05/2022 | 10 | 2544 | 22 387,20 |
| 9 | 1316 | 11 962,44 | |
12/05/2022 | 10 | 1207 | 10 452,62 |
| - | - | - | |
13/05/2022 | 6 | 678 | 5 810,46 |
| 2 | 802 | 7 009,48 | |
16/05/2022 | 8 | 1291 | 10 973,50 |
| - | - | - | |
17/05/2022 | 4 | 1012 | 8 551,40 |
| 7 | 1500 | 12 900,00 | |
18/05/2022 | - | - | - |
| 9 | 1131 | 10 031,97 | |
19/05/2022 | - | - | - |
| 5 | 619 | 5 614,33 | |
20/05/2022 | 2 | 251 | 2 233,90 |
| 3 | 500 | 4 500,00 | |
23/05/2022 | 3 | 1499 | 13 341,10 |
| 4 | 250 | 2 262,50 | |
24/05/2022 | 4 | 275 | 2 420,00 |
| 1 | 500 | 4 450,00 | |
25/05/2022 | - | - | - |
| 2 | 400 | 3 560,00 | |
26/05/2022 | 1 | 500 | 4 450,00 |
| 3 | 500 | 4 500,00 | |
27/05/2022 | 16 | 2488 | 21 645,60 |
| - | - | - | |
30/05/2022 | 3 | 1000 | 8 550,00 |
| 1 | 1 | 8,80 | |
31/05/2022 | 7 | 750 | 6 435,00 |
| 3 | 849 | 7 386,30 | |
01/06/2022 | - | - | - |
| 4 | 500 | 4 300,00 | |
02/06/2022 | 9 | 500 | 4 300,00 |
| 2 | 152 | 1 322,40 | |
03/06/2022 | 15 | 1200 | 10 224,00 |
| 2 | 149 | 1 296,30 | |
06/06/2022 | 3 | 600 | 5 100,00 |
| 1 | 1 | 8,60 | |
07/06/2022 | 1 | 1 | 8,51 |
| 3 | 189 | 1 625,40 | |
08/06/2022 | 4 | 150 | 1 282,50 |
| 4 | 411 | 3 538,71 | |
09/06/2022 | 3 | 655 | 5 619,90 |
| - | - | - | |
10/06/2022 | 8 | 845 | 7 233,20 |
| 3 | 500 | 4 350,00 | |
13/06/2022 | 21 | 2488 | 20 501,12 |
| - | - | - | |
14/06/2022 | 21 | 4100 | 32 267,00 |
| - | - | - | |
15/06/2022 | 5 | 1500 | 11 220,00 |
| - | - | - | |
16/06/2022 | 10 | 3000 | 21 540,00 |
| - | - | - | |
| Buy Side |
| Sell Side | |||||
| Number of | Number of | Traded volume in EUR |
| Number of | Number of | Traded volume in EUR | |
Total | 1534 | 269698 | 2 044 848,96 |
| 1127 | 202157 | 1 565 786,52 | |
17/06/2022 | 3 | 1000 | 7 000,00 |
| 1 | 500 | 3 600,00 | |
20/06/2022 | 7 | 1000 | 7 000,00 |
| 3 | 971 | 6 942,65 | |
21/06/2022 | 1 | 500 | 3 550,00 |
| 3 | 180 | 1 299,60 | |
22/06/2022 | 16 | 4500 | 30 375,00 |
| 1 | 500 | 3 500,00 | |
23/06/2022 | 8 | 1000 | 6 650,00 |
| - | - | - | |
24/06/2022 | - | - | - |
| 5 | 500 | 3 350,00 | |
27/06/2022 | 10 | 2000 | 12 960,00 |
| 4 | 500 | 3 400,00 | |
28/06/2022 | 7 | 2500 | 15 325,00 |
| 1 | 1 | 6,50 | |
29/06/2022 | 18 | 6000 | 34 260,00 |
| 1 | 500 | 2 950,00 | |
30/06/2022 | - | - | - |
| 1 | 4 | 22,80 | |
01/07/2022 | 5 | 500 | 2 800,00 |
| 1 | 1 | 5,70 | |
04/07/2022 | - | - | - |
| 10 | 3495 | 21 389,40 | |
05/07/2022 | - | - | - |
| 6 | 622 | 3 806,64 | |
06/07/2022 | 3 | 1000 | 5 950,00 |
| 1 | 1 | 6,25 | |
07/07/2022 | 7 | 2500 | 14 400,00 |
| 1 | 1 | 6,00 | |
08/07/2022 | - | - | - |
| 3 | 602 | 3 503,64 | |
11/07/2022 | 10 | 1486 | 8 470,20 |
| 2 | 398 | 2 348,20 | |
13/07/2022 | 3 | 514 | 2 878,40 |
| - | - | - | |
14/07/2022 | 3 | 500 | 2 750,00 |
| 2 | 171 | 974,70 | |
15/07/2022 | 3 | 501 | 2 705,40 |
| 1 | 1 | 5,44 | |
18/07/2022 | 1 | 1 | 5,43 |
| 1 | 1 | 5,43 | |
19/07/2022 | 7 | 1501 | 7 805,20 |
| 1 | 1 | 5,33 | |
20/07/2022 | 1 | 500 | 2 500,00 |
| 4 | 500 | 2 600,00 | |
21/07/2022 | 1 | 500 | 2 450,00 |
| 2 | 149 | 759,90 | |
22/07/2022 | 1 | 1 | 4,92 |
| 3 | 352 | 1 795,20 | |
26/07/2022 | 3 | 501 | 2 454,90 |
| 1 | 1 | 4,96 | |
27/07/2022 | 1 | 1 | 4,91 |
| 1 | 1 | 4,91 | |
28/07/2022 | 1 | 500 | 2 450,00 |
| - | - | - | |
29/07/2022 | 3 | 1500 | 7 095,00 |
| 1 | 8 | 38,40 | |
01/08/2022 | 1 | 500 | 2 350,00 |
| 6 | 492 | 2 361,60 | |
02/08/2022 | - | - | - |
| 1 | 1 | 4,80 | |
03/08/2022 | 1 | 135 | 621,00 |
| - | - | - | |
04/08/2022 | 2 | 365 | 1 679,00 |
| - | - | - | |
05/08/2022 | 3 | 501 | 2 304,60 |
| 2 | 44 | 206,80 | |
08/08/2022 | - | - | - |
| 7 | 1456 | 6 988,80 | |
09/08/2022 | 2 | 1000 | 4 680,00 |
| 3 | 1000 | 4 850,00 | |
10/08/2022 | - | - | - |
| 5 | 750 | 3 615,00 | |
11/08/2022 | - | - | - |
| 6 | 2500 | 12 600,00 | |
| Buy Side |
| Sell Side | |||||
| Number of | Number of | Traded volume in EUR |
| Number of | Number of | Traded volume in EUR | |
Total | 1534 | 269698 | 2 044 848,96 |
| 1127 | 202157 | 1 565 786,52 | |
12/08/2022 | - | - | - |
| 5 | 2000 | 10 540,00 | |
15/08/2022 | 1 | 500 | 2 600,00 |
| 2 | 500 | 2 700,00 | |
16/08/2022 | 5 | 600 | 3 114,00 |
| - | - | - | |
17/08/2022 | 7 | 1600 | 7 984,00 |
| - | - | - | |
18/08/2022 | 1 | 1 | 4,96 |
| 1 | 1 | 4,96 | |
19/08/2022 | 3 | 1000 | 4 850,00 |
| 2 | 500 | 2 520,00 | |
22/08/2022 | 3 | 500 | 2 450,00 |
| - | - | - | |
23/08/2022 | 4 | 501 | 2 404,80 |
| 2 | 2 | 9,80 | |
24/08/2022 | 3 | 1001 | 4 754,75 |
| 5 | 499 | 2 445,10 | |
25/08/2022 | 5 | 500 | 2 350,00 |
| 1 | 500 | 2 400,00 | |
26/08/2022 | 3 | 501 | 2 354,70 |
| 1 | 346 | 1 660,80 | |
29/08/2022 | 1 | 499 | 2 295,40 |
| - | - | - | |
30/08/2022 | - | - | - |
| 7 | 1654 | 8 038,44 | |
01/09/2022 | 3 | 1500 | 6 750,00 |
| 2 | 24 | 112,80 | |
05/09/2022 | 1 | 500 | 2 190,00 |
| - | - | - | |
06/09/2022 | - | - | - |
| 7 | 500 | 2 200,00 | |
07/09/2022 | 9 | 1600 | 6 720,00 |
| 1 | 1 | 4,44 | |
08/09/2022 | 1 | 1 | 4,16 |
| 2 | 131 | 556,75 | |
09/09/2022 | - | - | - |
| 5 | 610 | 2 616,90 | |
12/09/2022 | 3 | 500 | 2 100,00 |
| 2 | 10 | 43,00 | |
13/09/2022 | 1 | 258 | 1 057,80 |
| 1 | 1 | 4,30 | |
14/09/2022 | 3 | 501 | 2 004,00 |
| 1 | 1 | 4,11 | |
15/09/2022 | 3 | 751 | 3 056,57 |
| 3 | 1000 | 4 100,00 | |
16/09/2022 | 4 | 500 | 2 050,00 |
| 4 | 751 | 3 154,20 | |
19/09/2022 | 3 | 749 | 3 010,98 |
| 2 | 500 | 2 150,00 | |
21/09/2022 | 6 | 1000 | 4 030,00 |
| - | - | - | |
22/09/2022 | 3 | 500 | 2 300,00 |
| 18 | 5474 | 25 837,28 | |
23/09/2022 | 12 | 3550 | 15 407,00 |
| - | - | - | |
26/09/2022 | 2 | 500 | 2 000,00 |
| 1 | 500 | 2 050,00 | |
27/09/2022 | 2 | 750 | 3 000,00 |
| 3 | 250 | 1 012,50 | |
28/09/2022 | 5 | 1250 | 4 925,00 |
| - | - | - | |
29/09/2022 | 3 | 1500 | 5 700,00 |
| 1 | 2 | 8,00 | |
30/09/2022 | 6 | 1500 | 5 475,00 |
| - | - | - | |
03/10/2022 | - | - | - |
| 3 | 350 | 1 316,00 | |
04/10/2022 | - | - | - |
| 7 | 1000 | 3 880,00 | |
05/10/2022 | 4 | 1467 | 5 589,27 |
| 3 | 948 | 3 754,08 | |
06/10/2022 | - | - | - |
| 25 | 6500 | 27 365,00 | |
07/10/2022 | 1 | 500 | 2 300,00 |
| 23 | 4566 | 21 505,86 | |
| Buy Side |
| Sell Side | |||||
| Number of | Number of | Traded volume in EUR |
| Number of | Number of | Traded volume in EUR | |
Total | 1534 | 269698 | 2 044 848,96 |
| 1127 | 202157 | 1 565 786,52 | |
10/10/2022 | 5 | 1000 | 6 350,00 |
| 34 | 10761 | 69 731,28 | |
11/10/2022 | 32 | 6500 | 39 975,00 |
| 18 | 4100 | 28 946,00 | |
12/10/2022 | 14 | 3000 | 17 250,00 |
| 4 | 1320 | 7 774,80 | |
13/10/2022 | 10 | 3000 | 16 140,00 |
| - | - | - | |
14/10/2022 | 2 | 500 | 2 800,00 |
| 18 | 4500 | 25 785,00 | |
17/10/2022 | - | - | - |
| 26 | 5997 | 38 500,74 | |
18/10/2022 | 12 | 3000 | 18 750,00 |
| 5 | 701 | 4 836,90 | |
19/10/2022 | 15 | 2500 | 15 100,00 |
| - | - | - | |
20/10/2022 | 3 | 501 | 3 056,10 |
| 6 | 2500 | 15 500,00 | |
21/10/2022 | 14 | 1499 | 8 994,00 |
| - | - | - | |
24/10/2022 | 4 | 1500 | 9 000,00 |
| 5 | 530 | 3 264,80 | |
25/10/2022 | 10 | 2100 | 12 096,00 |
| 7 | 770 | 4 604,60 | |
26/10/2022 | - | - | - |
| 16 | 2000 | 11 700,00 | |
27/10/2022 | 7 | 1000 | 6 050,00 |
| 4 | 1500 | 9 180,00 | |
28/10/2022 | 12 | 3001 | 17 765,92 |
| 3 | 501 | 3 056,10 | |
31/10/2022 | 51 | 13500 | 68 580,00 |
| - | - | - | |
01/11/2022 | 2 | 500 | 2 325,00 |
| 2 | 500 | 2 400,00 | |
03/11/2022 | 8 | 3650 | 16 498,00 |
| - | - | - | |
04/11/2022 | 6 | 1000 | 4 500,00 |
| 1 | 500 | 2 300,00 | |
07/11/2022 | 9 | 1800 | 7 884,00 |
| - | - | - | |
08/11/2022 | 7 | 1500 | 6 390,00 |
| 2 | 750 | 3 240,00 | |
09/11/2022 | 4 | 1000 | 4 330,00 |
| - | - | - | |
10/11/2022 | 13 | 1700 | 7 021,00 |
| 3 | 1000 | 4 180,00 | |
11/11/2022 | - | - | - |
| 5 | 990 | 4 257,00 | |
14/11/2022 | - | - | - |
| 9 | 2110 | 9 537,20 | |
15/11/2022 | 15 | 2851 | 12 401,85 |
| 1 | 1 | 4,49 | |
16/11/2022 | 7 | 1000 | 4 250,00 |
| 1 | 250 | 1 070,00 | |
17/11/2022 | 4 | 500 | 2 150,00 |
| 4 | 1250 | 5 437,50 | |
18/11/2022 | 8 | 1351 | 5 741,75 |
| 3 | 401 | 1 724,30 | |
21/11/2022 | 5 | 1000 | 4 150,00 |
| - | - | - | |
22/11/2022 | 10 | 1750 | 7 017,50 |
| 1 | 500 | 2 100,00 | |
23/11/2022 | 3 | 1500 | 5 955,00 |
| 4 | 750 | 3 015,00 | |
24/11/2022 | - | - | - |
| 1 | 500 | 2 000,00 | |
25/11/2022 | 4 | 1000 | 4 000,00 |
| 3 | 750 | 3 015,00 | |
28/11/2022 | 2 | 500 | 2 000,00 |
| 8 | 1000 | 4 080,00 | |
29/11/2022 | 3 | 750 | 3 240,00 |
| 17 | 3750 | 16 425,00 | |
30/11/2022 | 3 | 1000 | 4 250,00 |
| - | - | - | |
17/11/2022 | 4 | 500 | 2 150,00 |
| 4 | 1250 | 5 437,50 | |
| Buy Side |
| Sell Side | |||||
| Number of | Number of | Traded volume in EUR |
| Number of | Number of | Traded volume in EUR | |
Total | 1534 | 269698 | 2 044 848,96 |
| 1127 | 202157 | 1 565 786,52 | |
18/11/2022 | 8 | 1351 | 5 741,75 |
| 3 | 401 | 1 724,30 | |
21/11/2022 | 5 | 1000 | 4 150,00 |
| - | - | - | |
22/11/2022 | 10 | 1750 | 7 017,50 |
| 1 | 500 | 2 100,00 | |
23/11/2022 | 3 | 1500 | 5 955,00 |
| 4 | 750 | 3 015,00 | |
24/11/2022 | - | - | - |
| 1 | 500 | 2 000,00 | |
25/11/2022 | 4 | 1000 | 4 000,00 |
| 3 | 750 | 3 015,00 | |
28/11/2022 | 2 | 500 | 2 000,00 |
| 8 | 1000 | 4 080,00 | |
29/11/2022 | 3 | 750 | 3 240,00 |
| 17 | 3750 | 16 425,00 | |
30/11/2022 | 3 | 1000 | 4 250,00 |
| - | - | - | |
05/12/2022 | - | - | - |
| 3 | 598 | 2 583,36 | |
06/12/2022 | 4 | 701 | 3 007,29 |
| 6 | 701 | 3 021,31 | |
07/12/2022 | 12 | 1750 | 7 367,50 |
| - | - | - | |
08/12/2022 | 4 | 751 | 3 094,12 |
| 1 | 1 | 4,18 | |
09/12/2022 | 1 | 1 | 4,09 |
| 2 | 40 | 166,00 | |
12/12/2022 | 6 | 850 | 3 468,00 |
| 1 | 1 | 4,15 | |
13/12/2022 | 1 | 1 | 4,07 |
| 6 | 1211 | 5 025,65 | |
14/12/2022 | - | - | - |
| 3 | 258 | 1 083,60 | |
15/12/2022 | 11 | 1001 | 4 104,10 |
| 1 | 1 | 4,18 | |
16/12/2022 | 3 | 251 | 1 016,55 |
| 2 | 201 | 818,07 | |
19/12/2022 | 4 | 255 | 1 032,75 |
| 15 | 3944 | 16 880,32 | |
20/12/2022 | 8 | 750 | 3 232,50 |
| 1 | 180 | 783,00 | |
21/12/2022 | 2 | 500 | 2 150,00 |
| 3 | 250 | 1 080,00 | |
22/12/2022 | 2 | 1000 | 4 280,00 |
| 10 | 1250 | 5 462,50 | |
23/12/2022 | 1 | 1 | 4,40 |
| 7 | 1501 | 6 679,45 | |
28/12/2022 | 3 | 501 | 2 204,40 |
| 1 | 1 | 4,44 | |
29/12/2022 | - | - | - |
| 7 | 2000 | 8 980,00 | |
30/12/2022 | 2 | 500 | 2 235,00 |
| - | - | - | |
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with NASH, mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate, has a pipeline of two preclinical programs and continues to explore other development opportunities to add to its pipeline.
Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. In 2020, Inventiva reported positive results from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and received Breakthrough Therapy and Fast Track status from the U.S. Food and Drug Administration (“FDA”) for lanifibranor in the treatment of NASH.
Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is in the process of selecting an oncology development candidate for its Hippo signaling pathway program.
The Company has a scientific team of approximately 80 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.
Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com.
Contacts
Inventiva | Brunswick Group | Westwicke, an ICR Company |
|
|
|
|
|
|
Important Notice
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, expectations with respect to the pivotal Phase III clinical trial evaluating lanifibranor in patients with NASH, including recruitment of patients for that trial, the Company’s ability to satisfy conditions precedent to draw down on the second tranche under the EIB facility, potential future financings or strategic transactions, milestone payments and royalties, the Company’s ability to exercise its rights under the EIB facility, including its call right and right of first refusal, expectations with respect to EIB’s rights under the EIB facility and EIB’s potential exercise of warrants, the expected use of proceeds from the EIB facility, and the sufficiency of Inventiva’s cash resources and cash runway. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Future events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals. Actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinical trials may not support Inventiva's product candidate claims, Inventiva may encounter substantial delays in its clinical trials or Inventiva may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrolment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva’s business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by the current COVID-19 pandemic and geopolitical events, such as the conflict between Russia and Ukraine, related sanctions and related impacts and potential impacts on the initiation, enrolment and completion of Inventiva’s clinical trials on anticipated timelines and macroeconomic conditions, including global inflation and uncertain financial markets or at all. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.
Please refer to the Universal Registration Document for the year ended December 31, 2021 filed with the Autorité des Marchés Financiers on March 11, 2022, the Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 11, 2022 and the financial report for the first half of 2022 filed with the Securities and Exchange Commission on September 22, 2022 for additional information in relation to such factors, risks and uncertainties.
All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above.
Attachment
